Drugs that contain Ivacaftor

1. List of Kalydeco drug patents

KALYDECO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US11564916 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

Do you want to check out KALYDECO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Market Authorisation Date: 31 January, 2012

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...

Dosage: TABLET;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

KALYDECO family patents

56

United States

23

European Union

15

Japan

11

Australia

10

China

9

Israel

9

New Zealand

9

Spain

8

Croatia

8

Denmark

8

Portugal

8

Poland

8

RS

8

Hungary

8

Lithuania

7

Canada

7

Hong Kong

7

Slovenia

7

Mexico

6

ME

6

Cyprus

6

Russia

5

Korea, Republic of

5

Brazil

3

South Africa

1

Luxembourg

EA

1

EA

1

Netherlands

1

Chile

1

Singapore

1

Ukraine

1

Norway

2. List of Kalydeco drug patents

KALYDECO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US11564916 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

US11147770 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Feb, 2033

(9 years from now)

Do you want to check out KALYDECO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Market Authorisation Date: 17 March, 2015

Treatment: Treatment of a moderate mild clinical phenotype of cf using ivacaftor in a patient age 6 months to <6 years who has one cftr mutation repsonsive to ivacaftor based on clinical and/or in vitro assay da...

Dosage: GRANULE;ORAL

How can I launch a generic of KALYDECO before it's patent expiration?
More Information on Dosage

KALYDECO family patents

66

United States

24

European Union

17

Japan

12

Australia

12

China

11

Israel

10

New Zealand

9

Spain

9

Hong Kong

8

Croatia

8

Canada

8

Denmark

8

Portugal

8

Russia

8

Poland

8

Mexico

8

RS

8

Hungary

8

Lithuania

7

Slovenia

6

ME

6

Cyprus

5

Korea, Republic of

5

Brazil

4

South Africa

1

Luxembourg

EA

1

EA

1

Netherlands

1

Chile

1

Singapore

1

Ukraine

1

Norway

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic